Clinical Trials Group Center for Cancer Research National Cancer Institute
Oncology
Dr. James L. Gulley, MD
James Gulley is an expert in the field of Oncology. He studied medicine at Loma Linda University School of Medicine. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "Top Doctors:Baltimore Area", "Top Doctors:Washington DC Area" and "Top Doctors:Washington-Baltimore". Dr. James L. Gulley is a published MD. He has 99 papers published. The most current publication "Prospects for the future of prostate cancer vaccines."
Publications
- Prospects for the future of Prostate cancer vaccines.
- Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
- The impact of leukapheresis on immune-cell number and function in patients with advanced Cancer.
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
- Moving the goal posts in Prostate cancer trials.
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: E...
- Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung Cancer.
- Adding fuel to the fire: Immunogenic intensification.
- Therapeutic vaccines as a promising treatment modality against Prostate cancer: rationale and recent advances.
- Recent advances in the use of therapeutic Cancer vaccines in genitourinary malignancies.
- Humoral response to a viral glycan correlates with survival on PROSTVAC-VF.
- Nivolumab: promising survival signal coupled with limited toxicity raises expectations.
- Therapeutic vaccines and immunotherapy in castration-resistant Prostate cancer: current progress and clinical applications.
- Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer.
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant Prostate cancer patients: immune correlates.
- Pan-Bcl-2 Inhibitor, GX15-070 (Obatoclax), Decreases Human T Regulatory Lymphocytes while Preserving Effector T Lymphocytes: A Rationale for Its Use in Combination Imm...
- Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets.
- Immunotherapy and therapeutic vaccines in Prostate cancer: an update on current strategies and clinical implications.
- Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
- Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.
- Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human Prostate cancer.
- Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
- Prostate cancer: Intermediate efficacy end points to assess modern therapies.
- Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant Prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
- Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant Prostate cancer.
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive Prostate cancer.
- Soluble CD27-Pool in Humans May Contribute to T Cell Activation and Tumor Immunity.
- Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF.
- Ipilimumab in Prostate cancer.
- Phase II clinical trial of cediranib in patients with metastatic castration-resistant Prostate cancer.
- Demystifying immunotherapy in Prostate cancer: understanding current and future treatment strategies.
- The role of soluble CD40L in immunosuppression.
- Progress in Prostate cancer imaging.
- Strategies for optimizing the clinical impact of immunotherapeutic agents such as sipuleucel-T in Prostate cancer.
- Elevated serum soluble CD40 ligand in Cancer patients may play an immunosuppressive role.
- Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity.
- Therapeutic vaccines: The ultimate personalized therapy?
- The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology.
- Clinical evaluation of TRICOM vector therapeutic Cancer vaccines.
- Poxviral vectors for Cancer immunotherapy.
- Endpoints, patient selection, and biomarkers in the design of clinical trials for Cancer vaccines.
- A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer.
- Initial PSA Oscillations Precede Prolonged Stable Disease in a Patient Treated With a Therapeutic Cancer Vaccine.
- A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal maligna...
- Prostate Cancer Immunotherapy.
- Highlights on FOXO3 and tumor-associated dendritic cells in Prostate cancer.
- Immunotherapy for Prostate cancer: recent advances, lessons learned, and areas for further research.
- Maturation of human dendritic cells with Saccharomyces cerevisiae (yeast) reduces the number and function of regulatory T cells and enhances the ratio of antigen-speci...
- Tumor regression and growth rates determined in five intramural NCI Prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.
- IgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacy.
- Immunologic monitoring of cellular immune responses in Cancer vaccine therapy.
- The current and emerging role of immunotherapy in Prostate cancer.
- A viral vaccine encoding Prostate-specific antigen induces antigen spreading to a common set of self-proteins in Prostate cancer patients.
- Targeting the immune system in non-small-cell lung Cancer: bridging the gap between promising concept and therapeutic reality.
- Vaccines as monotherapy and in combination therapy for Prostate cancer.
- A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant Prostate cancer.
- Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant Prostate cancer.
- Treatment of castration-resistant Prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway.
- Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant Prostate cancer.
- Therapeutic cancer vaccines in Prostate cancer: the paradox of improved survival without changes in time to progression.
- Phase I study of oral lenalidomide in patients with refractory metastatic Cancer.
- A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent Prostate cancer treated with intermittent androgen ablation.
- Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant Prostate cancer treated with anti-angiogenic agents.
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic Prostate cancer.
- Safety and immunologic response of a viral vaccine to Prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an ...
- Synergizing radiation therapy and immunotherapy for curing incurable Cancers. Opportunities and challenges.
- Analysis of overall survival in patients with nonmetastatic castration-resistant Prostate cancer treated with vaccine, nilutamide, and combination therapy.
- Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
- Paradigm shifts in Cancer vaccine therapy.
- Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with Prostate cancer.
- A phase II clinical trial of sorafenib in androgen-independent Prostate cancer.
- Clinical safety of a viral vector based Prostate cancer vaccine strategy.
- Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent Prostate cancer and extensive bone metastases.
- Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
- Cancer vaccines: moving beyond current paradigms.
- Phase I trial of an enhanced Prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent Prostate cancer.
- Significant Prostate-specific antigen (PSA) response to low-dose ketoconazole in a patient with non-metastatic androgen-independent Prostate cancer (AIPC) and a review...
- Combining Vaccines with Conventional Therapies for Cancer.
- A pilot study of CTLA-4 blockade after Cancer vaccine failure in patients with advanced malignancy.
- Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of Prostate cancer.
- Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
- Early treatment gets the benefit.
- Immunotherapy for Prostate cancer: what's the future?
- Even more cost savings?
- A phase I feasibility study of an intraprostatic Prostate-specific antigen-based vaccine in patients with Prostate cancer with local failure after radiation therapy or...
- A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast Cancer (NCI 05-C-02...
- Therapeutic vaccines for Prostate cancer.
- A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
- A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent Prostate cancer.
- Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
- Costimulatory molecules as adjuvants for immunotherapy.
- Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory Prostate cancer.
- Androgen deprivation therapy for Prostate cancer.
- Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized Prostate cancer.
- A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinica...
- Prolonged response to nilutamide in a patient with stage D0.5 Prostate cancer who previously failed androgen deprivation therapy.
- Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
- Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colon...
Schools
Loma Linda University School Of Medicine
Emory University School Of Med
National Canc Institute
Conditions Treated
- Prostate Cancer
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Top Doctors:Baltimore Area
- Top Doctors:Washington DC Area
- Top Doctors:Washington-Baltimore
Education
-
National Institutes of Health Clinical Center -
Emory University -
Loma Linda University School of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Richard Piekarz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maurcio Burotto Pichun, MD |
|
|
Dr. Philip M. Arlen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adrian M. Senderowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley Lipkowitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey S. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Lechleider, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sam O. Wanko, MD |
|
|
Dr. Carolyn B. Hendricks, MD
This Doctor is OpenDoctor Recommended.
|